Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
  • Channels
Advanced Search
bioRxiv is receiving many new papers on coronavirus 2019-nCoV.   A reminder: these are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.
New Results
  • This article has been withdrawn. Click here for details
67 comments

Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag

Prashant Pradhan, Ashutosh Kumar Pandey, Akhilesh Mishra, Parul Gupta, Praveen Kumar Tripathi, Manoj Balakrishnan Menon, James Gomes, Perumal Vivekanandan, Bishwajit Kundu
doi: https://doi.org/10.1101/2020.01.30.927871
This article is a preprint and has not been certified by peer review [what does this mean?].
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Abstract

We are currently witnessing a major epidemic caused by the 2019 novel coronavirus (2019-nCoV). The evolution of 2019-nCoV remains elusive. We found 4 insertions in the spike glycoprotein (S) which are unique to the 2019-nCoV and are not present in other coronaviruses. Importantly, amino acid residues in all the 4 inserts have identity or similarity to those in the HIV-1 gp120 or HIV-1 Gag. Interestingly, despite the inserts being discontinuous on the primary amino acid sequence, 3D-modelling of the 2019-nCoV suggests that they converge to constitute the receptor binding site. The finding of 4 unique inserts in the 2019-nCoV, all of which have identity /similarity to amino acid residues in key structural proteins of HIV-1 is unlikely to be fortuitous in nature. This work provides yet unknown insights on 2019-nCoV and sheds light on the evolution and pathogenicity of this virus with important implications for diagnosis of this virus.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 31, 2020.
Download PDF

Supplementary Material

Email
Share
Citation Tools

Subject Area

  • Evolutionary Biology
Subject Areas
All Articles
  • Animal Behavior and Cognition (1639)
  • Biochemistry (2710)
  • Bioengineering (1894)
  • Bioinformatics (10196)
  • Biophysics (4169)
  • Cancer Biology (3196)
  • Cell Biology (4516)
  • Clinical Trials* (135)
  • Developmental Biology (2830)
  • Ecology (4435)
  • Epidemiology* (2039)
  • Evolutionary Biology (7210)
  • Genetics (5460)
  • Genomics (6792)
  • Immunology (2372)
  • Microbiology (7447)
  • Molecular Biology (2968)
  • Neuroscience (18513)
  • Paleontology (135)
  • Pathology (470)
  • Pharmacology and Toxicology (775)
  • Physiology (1145)
  • Plant Biology (2690)
  • Scientific Communication and Education (679)
  • Synthetic Biology (883)
  • Systems Biology (2835)
  • Zoology (465)
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.